Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned

Ovid Therapeutics Inc.

• Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.
• Cash $165.6M as of Mar 31, 2026; plus $27.3M in April from warrant exercises; runway into 2029.
• Dosed first healthy volunteer in Phase 1 study of OV4071, oral KCC2 direct activator, for psychosis.
• OV329 shows favorable safety/PK up to 9 mg; Phase 2 for focal onset seizures and TSC/infantile spasms planned.
• Raised $60.0M gross from March 2026 PIPE and $53.9M from Series A warrant exercises (Oct 2025 PIPE).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.